BC Innovations | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BC Innovations | Nov 22, 2019
Product Development

The quiet disrupters: DNA-encoded and RNA-encoded antibodies

A new approach to streamlining biologics manufacturing could soon catch on--encoding the therapies in DNA or RNA, which enjoins the patient to produce the proteins in vivo . While the biggest upside may be the speed...
BC Innovations | Nov 18, 2019
Distillery Therapeutics

Tyrosine kinase inhibitors for the treatment of pemphigus

DISEASE CATEGORY: Autoimmune disease INDICATION: Pemphigus Tyrosine kinase inhibitors including the dual BCR-ABL/c-Kit inhibitor imatinib could treat pemphigus, an autoimmune blistering disorder. Pemphigus is caused by antibodies against the keratinocyte adhesion molecule DSG3. Imatinib reduced...
BC Innovations | Oct 17, 2019
Distillery Therapeutics

CPS-based bioconjugate vaccine for hypervirulent Klebsiella

DISEASE CATEGORY: Infectious disease INDICATION: Gram-negative bacterial infection A K. pneumoniae CPS-based glycoconjugate vaccine could protect mice against lethal infection by K. pneumoniae . The vaccine against K. pneumoniae serotypes K1 and K2, which cause most...
BC Innovations | Oct 7, 2019
Distillery Therapeutics

Bispecific cytokine fusion for Type II diabetes

DISEASE CATEGORY: Endocrine/metabolic disease INDICATION: Diabetes A chimeric protein derived from two cytokines previously shown to modify food intake, IL-6 and CNTF, could treat Type II diabetes. The chimeric cytokine is based on IL-6, with...
BC Extra | Jul 30, 2019
Company News

July 29 Company Quick Takes: Dupixent sales boost Sanofi; plus Twist, J&J, Alkermes and more

Despite multibillion dollar impairment, Sanofi beats on 2Q19 earnings  Sanofi (Euronext:SAN; NASDAQ:SNY) reported 2Q19 sales of €496 million from dermatitis and asthma drug Dupixent dupilumab, beating the Street's estimate of €411 million. The pharma also...
BC Innovations | Jul 11, 2019
Translation in Brief

Fc sugar additions control fetal transfer of maternal antibodies

Two groups have identified determinants of antibody transfer across the placenta, paving a way to maternal delivery of therapies that boost neonatal protection against infections. The teams homed in on IgG Fc sugar additions as...
BC Innovations | May 20, 2019
Distillery Therapeutics

HIST4H4 inhibition to treat atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Mouse studies suggest inhibiting HIST4H4 or its interaction with the cell membrane could help treat atherosclerosis. In a mouse model of atherosclerosis, a mAb against HIST4H4 or a cyclical peptide...
BC Innovations | May 6, 2019
Distillery Therapeutics

ADORA2A identified as a thrombosis target

DISEASE CATEGORY: Cardiovascular INDICATION: Thrombosis Cell culture and mouse studies suggest agonizing ADORA2A could help treat thrombosis. In primary human and mouse neutrophils treated with IgG from patients with antiphospholipid syndrome (APS), which is associated...
BC Innovations | Apr 15, 2019
Distillery Therapeutics

MedImmune's bispecific mAb for Pseudomonas-related ocular keratitis

DISEASE CATEGORY: Infectious disease INDICATION: Pseudomonas Mouse studies suggest MEDI3902, a bispecific mAb against P. aeruginosa Psl and PcrV, could help treat ocular keratitis caused by P. aeruginosa infection. In a mouse model of bacterial...
Items per page:
1 - 10 of 1107